{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:14:28Z","timestamp":1792124068280,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T00:00:00Z","timestamp":1286236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s11095-010-0262-z","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T17:08:34Z","timestamp":1286212114000},"page":"2633-2645","source":"Crossref","is-referenced-by-count":23,"title":["Population Pharmacokinetic Analysis of Blood and Joint Synovial Fluid Concentrations of Robenacoxib from Healthy Dogs and Dogs with Osteoarthritis"],"prefix":"10.1007","volume":"27","author":[{"given":"Hanna E.","family":"Silber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Burgener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M.","family":"Letellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Peyrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome M.","family":"Giraudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,5]]},"reference":[{"issue":"3","key":"262_CR1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrd1034","volume":"2","author":"RJ Flower","year":"2003","unstructured":"Flower RJ. The development of COX-2 inhibitors. Nat Rev Drug Discov. 2003;2(3):179\u201391.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"262_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2885.2004.00618.x","volume":"27","author":"P Lees","year":"2004","unstructured":"Lees P, Giraudel J, Landoni MF, Toutain PL. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. J Vet Pharmacol Ther. 2004;27(6):491\u2013502.","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"262_CR3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2885.2008.01031.x","volume":"32","author":"JM Giraudel","year":"2009","unstructured":"Giraudel JM, Toutain PL, King JN, Lees P. Differential inhibition of cyclooxygenase isoenzymes in the cat by the COX-2 selective drug robenacoxib. J Vet Pharmacol Ther. 2009;32(1):31\u201340.","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"262_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2885.2008.00962.x","volume":"32","author":"JN King","year":"2009","unstructured":"King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W, et al. Pre-clinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. J Vet Pharmacol Ther. 2009;32(1):1\u201317.","journal-title":"J Vet Pharmacol Ther"},{"issue":"3","key":"262_CR5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.rvsc.2009.11.002","volume":"88","author":"JN King","year":"2010","unstructured":"King JN, Rudaz C, Borer L, Jung M, Seewald W, Lees P. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Res Vet Sci. 2010;88(3):497\u2013506.","journal-title":"Res Vet Sci"},{"issue":"1","key":"262_CR6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2885.2008.01035.x","volume":"32","author":"M Jung","year":"2009","unstructured":"Jung M, Lees P, Seewald W, King JN. Analytical determination and pharmacokinetics of robenacoxib in the dog. J Vet Pharmacol Ther. 2009;32(1):41\u20138.","journal-title":"J Vet Pharmacol Ther"},{"key":"262_CR7","unstructured":"Gruet P, Seewald W, King JN. Subcutaneous and oral robenacoxib versus meloxicam for the treatment of acute pain and inflammation associated with orthopedic surgery in dogs; a randomized, non-inferiority field study. Am J Vet Res. 2010; accepted for publication."},{"key":"262_CR8","doi-asserted-by":"crossref","unstructured":"Reymond N, Speranza C, Gruet P, Seewald W, King JN. Robenacoxib versus carprofen for the treatment of canine osteoarthritis; a randomized, non-inferiority field study. J Vet Pharmacol Therap. 2010; submitted for publication.","DOI":"10.1111\/j.1365-2885.2011.01297.x"},{"key":"262_CR9","doi-asserted-by":"crossref","unstructured":"King JN, Arnaud JP, Goldenthal EI, Gruet P, Jung M, Seewald W, Lees P. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2. J Vet Pharmacol Therap. 2010; doi: 10.1111\/j.1365-2885.2010.01209.x .","DOI":"10.1111\/j.1365-2885.2010.01209.x"},{"issue":"4","key":"262_CR10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.bjp.0706078","volume":"144","author":"R Esser","year":"2005","unstructured":"Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005;144(4):538\u201350.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"262_CR11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200443070-00003","volume":"43","author":"G Scott","year":"2004","unstructured":"Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet. 2004;43(7):467\u201378.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"262_CR12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/rheumatology\/kem070","volume":"46","author":"K Brune","year":"2007","unstructured":"Brune K, Furst DE. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology. 2007;46(6):911\u20139.","journal-title":"Rheumatology"},{"issue":"2","key":"262_CR13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2885.2009.01117.x","volume":"33","author":"VB Schmid","year":"2010","unstructured":"Schmid VB, Spreng DE, Seewald W, Jung M, Lees P, King JN. Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in the dog. J Vet Pharmacol Ther. 2010;33(2):118\u201331.","journal-title":"J Vet Pharmacol Ther"},{"issue":"5","key":"262_CR14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Parmacodyn. 2007;34(5):711\u201326.","journal-title":"J Pharmacokinet Parmacodyn"},{"issue":"3","key":"262_CR15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpt1979253358","volume":"25","author":"LB Sheiner","year":"1979","unstructured":"Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979;25(3):358\u201371.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"262_CR16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","volume":"21","author":"MO Karlsson","year":"1993","unstructured":"Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21(6):735\u201350.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"262_CR17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10928-009-9112-1","volume":"36","author":"HE Silber","year":"2009","unstructured":"Silber HE, Kjellsson MC, Karlsson MO. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion. J Pharmacokinet Pharmacodyn. 2009;36(1):81\u201399.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"262_CR18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Biopharm. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"262_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose\u2014an S-plus based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"262_CR20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558\u201369.","journal-title":"AAPS J"},{"issue":"17","key":"262_CR21","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","volume":"96","author":"TD Warner","year":"1999","unstructured":"Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. J Proc Nat Acad Sci USA. 1999;96(17):7563\u20138.","journal-title":"J Proc Nat Acad Sci USA"},{"issue":"2\u20133","key":"262_CR22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0163-7258(01)00165-6","volume":"92","author":"KW Renton","year":"2001","unstructured":"Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther. 2001;92(2\u20133):147\u201363.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"262_CR23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425255.1.4.629","volume":"1","author":"KW Renton","year":"2005","unstructured":"Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005;1(4):629\u201340.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"262_CR24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1023\/A:1023246832321","volume":"20","author":"M Qian","year":"2003","unstructured":"Qian M, West W, Wu JT, Lu B, Christ DD. Development of a dog microdialysis model for determining synovial fluid pharmacokinetics of anti-arthritis compounds exemplified by methotrexate. Pharm Res. 2003;20(4):605\u201310.","journal-title":"Pharm Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-010-0262-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-010-0262-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-010-0262-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T02:39:27Z","timestamp":1559702367000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-010-0262-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,5]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1007\/s11095-010-0262-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,5]]}}}